3QXT | pdb_00003qxt

Structure of an Anti-Methotrexate CDR1-3 Graft VHH Antibody in Complex with Methotrexate


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 
    0.195 (Depositor), 0.205 (DCC) 
  • R-Value Work: 
    0.175 (Depositor), 0.185 (DCC) 
  • R-Value Observed: 
    0.176 (Depositor) 

wwPDB Validation 3D Report Full Report

Validation slider image for 3QXT

Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history

Literature

An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop.

Fanning, S.W.Horn, J.R.

(2011) Protein Sci 20: 1196-1207

  • DOI: https://doi.org/10.1002/pro.648
  • Primary Citation Related Structures: 
    3QXT, 3QXU, 3QXV, 3QXW

  • PubMed Abstract: 

    Conventional anti-hapten antibodies typically bind low-molecular weight compounds (haptens) in the crevice between the variable heavy and light chains. Conversely, heavy chain-only camelid antibodies, which lack a light chain, must rely entirely on a single variable domain to recognize haptens. While several anti-hapten VHHs have been generated, little is known regarding the underlying structural and thermodynamic basis for hapten recognition. Here, an anti-methotrexate VHH (anti-MTX VHH) was generated using grafting methods whereby the three complementarity determining regions (CDRs) were inserted onto an existing VHH framework. Thermodynamic analysis of the anti-MTX VHH CDR1-3 Graft revealed a micromolar binding affinity, while the crystal structure of the complex revealed a somewhat surprising noncanonical binding site which involved MTX tunneling under the CDR1 loop. Due to the close proximity of MTX to CDR4, a nonhypervariable loop, the CDR4 loop sequence was subsequently introduced into the CDR1-3 graft, which resulted in a dramatic 1000-fold increase in the binding affinity. Crystal structure analysis of both the free and complex anti-MTX CDR1-4 graft revealed CDR4 plays a significant role in both intermolecular contacts and binding site conformation that appear to contribute toward high affinity binding. Additionally, the anti-MTX VHH possessed relatively high specificity for MTX over closely related compounds aminopterin and folate, demonstrating that VHH domains are capable of binding low-molecular weight ligands with high affinity and specificity, despite their reduced interface.


  • Organizational Affiliation
    • Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL 60115, USA.

Macromolecule Content 

  • Total Structure Weight: 28.43 kDa 
  • Atom Count: 2,228 
  • Modeled Residue Count: 248 
  • Deposited Residue Count: 252 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Anti-Methotrexate CDR1-3 Graft VHH
A, B
126Lama glamaMutation(s): 0 

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free:  0.195 (Depositor), 0.205 (DCC) 
  • R-Value Work:  0.175 (Depositor), 0.185 (DCC) 
  • R-Value Observed: 0.176 (Depositor) 
Space Group: P 61 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 103.063α = 90
b = 103.063β = 90
c = 157.073γ = 120
Software Package:
Software NamePurpose
HKL-2000data collection
PHASERphasing
REFMACrefinement
DENZOdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2011-07-06
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2013-09-11
    Changes: Structure summary
  • Version 1.3: 2024-11-27
    Changes: Data collection, Database references, Derived calculations, Structure summary